Table 1.
Patient and tumour characteristics among patients with clinically node‐positive disease
| No. of patients* (n = 139) | |
|---|---|
| Treating centre | |
| University Medical Centre Utrecht | 23 (16·5) |
| Amphia Hospital | 22 (15·8) |
| Medical Centre Haaglanden | 59 (42·4) |
| Alrijne Hospital | 35 (25·2) |
| Age (years) † | 56 (26–82) |
| Clinical tumour category ‡ | |
| cT1 | 19 (14) |
| cT2 | 78 (57·4) |
| cT3 | 27 (19·9) |
| cT4 | 12 (8·8) |
| Clinical node category | |
| cN1 | 102 (73·4) |
| cN2 | 26 (18·7) |
| cN3 | 11 (7·9) |
| Histology | |
| Ductal | 117 (84·2) |
| Lobular | 10 (7·2) |
| Ductulolobular | 7 (5·0) |
| Other§ | 5 (3·6) |
| Molecular subtype | |
| HR+/HER2+ | 24 (17·3) |
| HR–/HER2+ | 22 (15·8) |
| HR+/HER2– | 68 (48·9) |
| Triple‐negative | 25 (18·0) |
| Method of confirmation of nodal positivity | |
| FNAC | 126 (90·6) |
| CNB | 13 (9·4) |
*
Values in parentheses are percentages unless indicated otherwise;
†
values are median (range).
‡
Data available for 136 patients; one patient had relapse in mastectomy scar (patient A), one had ductal carcinoma in situ after neoadjuvant systemic therapy (NST) but no histopathological diagnosis before NST (patient B), and one had axillary relapse without signs of local relapse (patient C).
§
Tubulolobular carcinoma in one patient, tubular carcinoma in one patient, data missing for three patients (including patients B and C). HR, hormone receptor; HER2, human epidermal growth factor receptor 2; FNAC, fine‐needle aspiration cytology; CNB, core needle biopsy.